Optimal management of portal vein thrombosis in patients with liver cirrhosis: A review

被引：0

作者：

Huard G. ^{[1
]}

Bissonnette J. ^{[1
]}

Bilodeau M. ^{[1
]}

机构：

[1] Liver Unit, Hôpital Saint-Luc, Centre Hospitalier de l’Université de Montréal, 264, Boulevard René-Lévesque Est, Pavillon Édouard-Asselin, Bureau 318, Montréal, H2X 1P1, QC

来源：

Current Hepatology Reports | 2015年 / 14卷 / 3期

关键词：

Anticoagulation; Cirrhosis; Liver transplantation; Portal vein thrombosis;

D O I：

10.1007/s11901-015-0273-7

中图分类号：

学科分类号：

摘要：

Portal vein thrombosis (PVT) is a fairly common complication of cirrhosis, especially in patients with advanced liver disease and reduced portal vein flow velocity. Prospective studies have shown that its occurrence parallels rather than causes the progression of liver disease and that spontaneous regression is a frequent finding. PVT occurrence is associated with an increased mortality after liver transplantation. Treatment options include anticoagulation and insertion of a transjugular intrahepatic portosystemic shunt. Anticoagulation with vitamin K antagonists or low-molecular-weight heparins achieves partial or complete portal vein recanalization in most patients. Anticoagulation does not seem to increase the bleeding risk when proper prophylaxis of variceal bleeding is applied. Monitoring of anticoagulation difficulties exist, inherent to the coagulopathy of chronic liver disease. Placement of a transjugular intrahepat i c portosystemic shunt is an alternative in selected patients. Trials are underway to evaluate the potential benefit of PVT prophylaxis with low-molecular-weight heparins. © Springer Science+Business Media New York 2015.

引用

页码：203 / 211

页数：8

共 61 条

[1]

Chung J.W., Et al., Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: A propensity score matching analysis, Clin Mol Hepatol, 20, 4, pp. 384-391, (2014)

[2]

Rodriguez-Castro K.I., Et al., Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis, Liver Int, 32, 10, pp. 1465-1476, (2012)

[3]

Aldawood A., Et al., The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients, Thromb J, 9, 1, (2011)

[4]

Zocco M.A., Et al., Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development, J Hepatol, 51, 4, pp. 682-689, (2009)

[5]

Huard G., Bilodeau M., Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: A systematic review, Int J Hepatol, 2012, (2012)

[6]

Nery F., Et al., Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: Results of a longitudinal study, Hepatology, 61, 2, pp. 660-667, (2015)

[7]

Qi X., Et al., Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies, Eur J Intern Med, 26, 1, pp. 23-29, (2015)

[8]

Delgado M.G., Et al., Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis, Clin Gastroenterol Hepatol, 10, 7, pp. 776-783, (2012)

[9]

Tripodi A., Mannucci P.M., The coagulopathy of chronic liver disease, N Engl J Med, 365, 2, pp. 147-156, (2011)

[10]

Valla D.C., Thrombosis and anticoagulation in liver disease, Hepatology, 47, 4, pp. 1384-1393, (2008)

← 1 2 3 4 5 6 7 →